Literature DB >> 31289507

Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218.

Xuezhi Tong1, Pei Yang1, Kuanyu Wang2, Yanwei Liu1, Xiu Liu2, Xia Shan2, Ruoyu Huang2, Ke'Nan Zhang2, Jiangfei Wang1.   

Abstract

Accumulating evidence has revealed that survivin expression is associated with a malignant phenotype and poor prognosis in glioma. Survivin is also a potential target of microRNA (miRNA/miR)-218. The aim of the present study was to investigate the expression and function of survivin in glioblastoma, and to examine the association between survivin and miR-218. For that purpose, survivin mRNA levels were analyzed in 144 frozen samples of glioblastoma using whole-genome RNA sequencing. In vitro cell proliferation, migration, invasion and apoptosis assays were performed, and survivin expression was detected by western blotting. The results revealed that the mRNA expression levels of survivin were negatively and significantly associated with overall survival in glioblastoma. Further in vitro analyses suggested that miR-218 may inhibit the expression of survivin. Expression of miR-218 in the LN229 cell line was significantly lower than that in the immortalized human gliocyte HEB cell line. miR-218 markedly inhibited tumor cell proliferation, migration and invasion capacities, and decreased apoptosis. miR-218 also inhibited the expression of survivin. These results indicated that survivin may be a target of miR-218 and could serve as a predictive biomarker.

Entities:  

Keywords:  glioblastoma; miRNA-218; prognosis; proliferation; survivin

Year:  2019        PMID: 31289507      PMCID: PMC6539917          DOI: 10.3892/ol.2019.10335

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  7 in total

1.  Blockade of Nuclear Factor-Κb (NF-Κb) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells.

Authors:  Ali Nasrollahzadeh; Majid Momeny; Davood Bashash; Hassan Yousefi; Seyed Asadollah Mousavi; Seyed Hamidollah Ghaffari
Journal:  Rep Biochem Mol Biol       Date:  2022-01

2.  miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.

Authors:  Leisheng Wang; He En; Lei Yang; Yanbing Zhang; Baisheng Sun; Jianjiang Gao
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

Review 3.  Antitumor Activity of Curcumin in Glioblastoma.

Authors:  Blake C Walker; Sandeep Mittal
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

4.  3BDO inhibits the proliferation, epithelial-mesenchymal transition (EMT), and stemness via suppressing survivin in human glioblastoma cells.

Authors:  Zhaotao Wang; Yongping Li; Minyi Liu; Danmin Chen; Jiajie Lu; Yunxiang Ji; Zhou Xing; Yezhong Wang
Journal:  J Cancer       Date:  2022-01-16       Impact factor: 4.207

5.  miRNA‑218 targets multiple oncogenes and is a therapeutic target for osteosarcoma.

Authors:  Kentaro Sato; Eiji Osaka; Kyoko Fujiwara; Ryota Fujii; Tadateru Takayama; Yasuaki Tokuhashi; Kazuyoshi Nakanishi
Journal:  Oncol Rep       Date:  2022-03-16       Impact factor: 3.906

Review 6.  Current Immunotherapeutic Strategies for the Treatment of Glioblastoma.

Authors:  Mark Dapash; Brandyn Castro; David Hou; Catalina Lee-Chang
Journal:  Cancers (Basel)       Date:  2021-09-10       Impact factor: 6.639

Review 7.  Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.

Authors:  Francesca Persano; Giuseppe Gigli; Stefano Leporatti
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.